NEWPORT BEACH, Calif., (July 31, 2023) — The second annual Cali-RAD Fest (Reggae Against Duchenne) will return to The Beach House in Mission Beach on September 2, 2023, to benefit […]
– First participant is expected to be dosed in September 2023 with data anticipated in the second half of 2024 – – Cash runway extended through the end of 2025 […]
CLICK BELOW FOR A FEW WORDS FROM OUR TEAM AND SAREPTA: Sarepta Therapeutics’ gene therapy for Duchenne, SRP-9001, has been granted Accelerated Approval by the FDA for individuals with Duchenne […]
NEW YORK, June 15, 2023 – CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved […]
Tickets and Sponsorships Available in Support of Nonprofit Dedicated to Finding and Funding Cure for Duchenne Muscular Dystrophy Knoxville, TN. (June 5, 2023) – Knoxville Brewfest, the city’s most anticipated […]
Doug Levine, PT, a physical therapist instructor with CureDuchenne, and Kerry Johnson, senior director of community engagement, visited India in February to educate physical therapists, doctors, physical and occupational therapy […]
“CureDuchenne is a leader in funding pioneering research aimed at advancing the best possible therapies for DMD patients, and we value their vote of confidence and financial support of our snRNA-mediated exon skipping platform,” said Jim Burns, Ph.D., Locanabio’s chief executive officer.
My name is Debra Miller, founder and CEO of CureDuchenne, and the mother of an incredible son, Hawken, who has Duchenne muscular dystrophy. I’m here today to represent the voice of patient advocacy organizations serving those impacted by Duchenne – all of whom are in support of the accelerated approval of SRP-9001.
CureDuchenne Ventures announces an investment in Insmed Inc. to support the development of INS1201, their next generation intracerebroventricular (ICV) delivered AAV to directly address limitations of current gene therapy approaches.